Contact
Please use this form to send email to PR contact of this press release:
Tellus Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for Neonatal Brain Injury Program TT-20
TO:
Jason Kralic
Tellus Therapeutics, Inc.
+1 919-491-4995